VIR Quote, Financials, Valuation and Earnings

Johnson & Johnson has a net margin of -67975.42% compared to Vir Biotechnology, Inc.'s net margin of 20.83%. Vir Biotechnology, Inc.'s return on equity of -48.24% beat Johnson & Johnson's return on equity of 34.46%.

Vir Biotechnology, Inc. has a consensus price target of $16.56, signalling upside risk potential of 118.99%. On the other hand Johnson & Johnson has an analysts' consensus of $232.50 which suggests that it could fall by -4.12%. Given that Vir Biotechnology, Inc. has higher upside potential than Johnson & Johnson, analysts believe Vir Biotechnology, Inc. is more attractive than Johnson & Johnson.

Vir Biotechnology, Inc. has a beta of 1.693, which suggesting that the stock is 69.258% more volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.350, suggesting its less volatile than the S&P 500 by 64.977%.

Vir Biotechnology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 2.12% to investors and pays a quarterly dividend of $1.30 per share. Vir Biotechnology, Inc. pays -- of its earnings as a dividend. Johnson & Johnson pays out 46.59% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Vir Biotechnology, Inc. quarterly revenues are $240K, which are smaller than Johnson & Johnson quarterly revenues of $24.6B. Vir Biotechnology, Inc.'s net income of -$163.1M is lower than Johnson & Johnson's net income of $5.1B. Notably, Vir Biotechnology, Inc.'s price-to-earnings ratio is -- while Johnson & Johnson's PE ratio is 21.95x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vir Biotechnology, Inc. is 61.84x versus 6.25x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Merck & Co., Inc. has a net margin of -67975.42% compared to Vir Biotechnology, Inc.'s net margin of 18.06%. Vir Biotechnology, Inc.'s return on equity of -48.24% beat Merck & Co., Inc.'s return on equity of 39.63%.

Vir Biotechnology, Inc. has a consensus price target of $16.56, signalling upside risk potential of 118.99%. On the other hand Merck & Co., Inc. has an analysts' consensus of $126.00 which suggests that it could grow by 3.06%. Given that Vir Biotechnology, Inc. has higher upside potential than Merck & Co., Inc., analysts believe Vir Biotechnology, Inc. is more attractive than Merck & Co., Inc..

Vir Biotechnology, Inc. has a beta of 1.693, which suggesting that the stock is 69.258% more volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.280, suggesting its less volatile than the S&P 500 by 72.042%.

Vir Biotechnology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & Co., Inc. offers a yield of 2.68% to investors and pays a quarterly dividend of $0.85 per share. Vir Biotechnology, Inc. pays -- of its earnings as a dividend. Merck & Co., Inc. pays out 45.05% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Vir Biotechnology, Inc. quarterly revenues are $240K, which are smaller than Merck & Co., Inc. quarterly revenues of $16.4B. Vir Biotechnology, Inc.'s net income of -$163.1M is lower than Merck & Co., Inc.'s net income of $3B. Notably, Vir Biotechnology, Inc.'s price-to-earnings ratio is -- while Merck & Co., Inc.'s PE ratio is 16.81x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vir Biotechnology, Inc. is 61.84x versus 4.72x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Moderna, Inc. has a net margin of -67975.42% compared to Vir Biotechnology, Inc.'s net margin of -121.83%. Vir Biotechnology, Inc.'s return on equity of -48.24% beat Moderna, Inc.'s return on equity of -29.19%.

Vir Biotechnology, Inc. has a consensus price target of $16.56, signalling upside risk potential of 118.99%. On the other hand Moderna, Inc. has an analysts' consensus of $41.75 which suggests that it could fall by -16.28%. Given that Vir Biotechnology, Inc. has higher upside potential than Moderna, Inc., analysts believe Vir Biotechnology, Inc. is more attractive than Moderna, Inc..

Vir Biotechnology, Inc. has a beta of 1.693, which suggesting that the stock is 69.258% more volatile than S&P 500. In comparison Moderna, Inc. has a beta of 1.318, suggesting its more volatile than the S&P 500 by 31.821%.

Vir Biotechnology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vir Biotechnology, Inc. pays -- of its earnings as a dividend. Moderna, Inc. pays out -- of its earnings as a dividend.

Vir Biotechnology, Inc. quarterly revenues are $240K, which are smaller than Moderna, Inc. quarterly revenues of $678M. Vir Biotechnology, Inc.'s net income of -$163.1M is higher than Moderna, Inc.'s net income of -$826M. Notably, Vir Biotechnology, Inc.'s price-to-earnings ratio is -- while Moderna, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vir Biotechnology, Inc. is 61.84x versus 9.98x for Moderna, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Sensei Biotherapeutics, Inc. has a net margin of -67975.42% compared to Vir Biotechnology, Inc.'s net margin of --. Vir Biotechnology, Inc.'s return on equity of -48.24% beat Sensei Biotherapeutics, Inc.'s return on equity of -68.55%.

Vir Biotechnology, Inc. has a consensus price target of $16.56, signalling upside risk potential of 118.99%. On the other hand Sensei Biotherapeutics, Inc. has an analysts' consensus of $32.50 which suggests that it could grow by 4.48%. Given that Vir Biotechnology, Inc. has higher upside potential than Sensei Biotherapeutics, Inc., analysts believe Vir Biotechnology, Inc. is more attractive than Sensei Biotherapeutics, Inc..

Vir Biotechnology, Inc. has a beta of 1.693, which suggesting that the stock is 69.258% more volatile than S&P 500. In comparison Sensei Biotherapeutics, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Vir Biotechnology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sensei Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vir Biotechnology, Inc. pays -- of its earnings as a dividend. Sensei Biotherapeutics, Inc. pays out -- of its earnings as a dividend.

Vir Biotechnology, Inc. quarterly revenues are $240K, which are larger than Sensei Biotherapeutics, Inc. quarterly revenues of --. Vir Biotechnology, Inc.'s net income of -$163.1M is lower than Sensei Biotherapeutics, Inc.'s net income of -$4.9M. Notably, Vir Biotechnology, Inc.'s price-to-earnings ratio is -- while Sensei Biotherapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vir Biotechnology, Inc. is 61.84x versus -- for Sensei Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.